During the third phase of the clinical testing, the new Astrazeneca drug based on human antibodies showed an effectiveness of 77 percent in the control of coronavirus, the company reports in his press release.
The new AZD7442 preparation is a combination of two types of long-acting monoclonal antibodies. According to Astrazenec, it can provide protection against coronavirus throughout the year. However, earlier he showed efficiency only at 33 percent.
In the course of the new, third, the phase of clinical research AZD7442 reduced the risk of developing the symptoms of coronavirus by 77 percent compared with the placebo-salt solution. Of all 5197 participants in the study of the symptoms of coronavirus developed in 25 people.
Preliminary studies in vitro have shown that the drug neutralizes and new variants of coronavirus, including the “Delta” -Shtam. Currently, Astrazeneca is preparing to submit research results for conditional permit for the sale of the drug. “AZD7442 may be an important tool in our arsenal to help people who have not had enough vaccinations to return to normal life,” said Professor of the University of Mairon Levin.
The development of the drug was financed by the US authorities, which have already ordered more than 700 thousand his doses.